Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
SYNEOS HEALTH, INC. |
Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 42.98 USD | +0.02% | +0.47% | +17.18% | |
| Sep. 29 | Syneos Health, Inc.(NasdaqGS:SYNH) dropped from S&P 400 | CI |
| Sep. 29 | Syneos Health, Inc.(NasdaqGS:SYNH) dropped from S&P 400 Health Care | CI |
Financials (USD)
| Sales 2022 | 5,393 M | Sales 2023 * | - | Capitalization | 3 775 M |
|---|---|---|---|---|---|
| Net income 2022 | 266 M | Net income 2023 * | - | EV / Sales 2022 | 1,22x |
| Net Debt 2022 | 2,787 M | Net cash position 2023 * | - | EV / Sales 2023 * | - |
| P/E ratio 2022 | 14,2x | P/E ratio 2023 * | Employees | - | |
| Yield 2022 | - | Yield 2023 * |
-
| Free-Float | 59.05% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +0.02% | ||
| 1 week | +0.47% | ||
| 1 month | +0.61% | ||
| 3 months | +1.99% | ||
| 6 months | +20.66% | ||
| Current year | +17.18% |
1 week
42.97
42.99
1 month
42.6243.64
Current year
32.7443.64
1 year
22.8952.23
3 years
22.89104.18
5 years
22.89104.18
10 years
19.61104.18
| Managers | Title | Age | Since |
|---|---|---|---|
Michelle Keefe
CEO | Chief Executive Officer | 56 | 2022 |
Michael Bonello
DFI | Director of Finance/CFO | 54 | Jun. 30 |
Michael Brooks
COO | Chief Operating Officer | 49 | 2022 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michelle Keefe
BRD | Director/Board Member | 56 | 2022 |
James Momtazee
BRD | Director/Board Member | 51 | Sep. 27 |
Sumit Khatod
BRD | Director/Board Member | - | Sep. 27 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.82% | 8 M$ | -9.98% | ||
| 0.77% | 2 M$ | -7.95% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-09-27 | 42.98 | +0.02% | 7,386,241 |
| 23-09-26 | 42.97 | +0.44% | 3,562,832 |
Delayed Quote Nasdaq, September 27, 2023 at 04:00 pm EDT
More quotes
Syneos Health, Inc. is a biopharmaceutical solutions company that utilizes outsourced clinical drug development and commercialization services. The Company operates through two business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers global services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics that span Phase I to IV of clinical development. The Clinical Solutions segment offers individual services including product development, project management, protocol development, investigational site recruitment, and clinical monitoring. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions (public relations, advertising, and medical communications), and consulting services. The Company's customers include small, mid-sized, and large companies in the biopharmaceutical, biotechnology, and medical device industries.
Calendar
2023-11-01
- Q3 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
| 1st Jan change | Capi. (M$) | |
|---|---|---|
| +17.18% | 4 458 M $ | |
| -5.43% | 199 M $ | |
| 0.00% | 61 M $ | |
| -39.18% | 795 M $ | |
| +22.70% | 896 M $ | |
| -29.44% | 93 M $ | |
| +87.39% | 1 644 M $ | |
| -57.21% | 56 M $ | |
| -25.47% | 140 M $ | |
| -.--% | 431 M $ |
